vesnarinone has been researched along with Arrhythmia in 8 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "Vesnarinone is associated with a dose-dependent increase in mortality among patients with severe heart failure, an increase that is probably related to an increase in deaths due to arrhythmia." | 9.08 | A dose-dependent increase in mortality with vesnarinone among patients with severe heart failure. Vesnarinone Trial Investigators. ( Bourge, RC; Cohn, JN; DeMets, DL; Goldstein, SO; Gottlieb, SO; Greenberg, BH; Jaski, BE; Lorell, BH; McGrew, F; White, BG, 1998) |
| "Vesnarinone is associated with a dose-dependent increase in mortality among patients with severe heart failure, an increase that is probably related to an increase in deaths due to arrhythmia." | 5.08 | A dose-dependent increase in mortality with vesnarinone among patients with severe heart failure. Vesnarinone Trial Investigators. ( Bourge, RC; Cohn, JN; DeMets, DL; Goldstein, SO; Gottlieb, SO; Greenberg, BH; Jaski, BE; Lorell, BH; McGrew, F; White, BG, 1998) |
| "Influence of 4,5-dihydro-6-[1-[2-hydroxy-2-(4-cyanophenyl)ethyl]- 1,2,5,6,-tetrahydropyrido-4-yl]pyridazin-3(2H)-one (SCH00013) and vesnarinone (CAS 81840-15-5) on the arrhythmia experimentally induced by three different methods was investigated in dogs." | 3.70 | Investigation on SCH00013, a novel cardiotonic agent with Ca++ sensitizing action. 4th communication: influence on experimentally induced ventricular arrhythmia in dogs. ( Endoh, M; Hino, M; Sakato, M; Sugawara, H; Yoshimura, A; Yoshioka, K, 1999) |
| "Xamoterol was highly effective in patients with atrial fibrillation who not only had excessive tachycardia during exercise but marked bradycardia at night." | 1.28 | [How to select newly-developed oral inotropic agents: an evaluation based on their effects on heart rate and arrhythmias]. ( Fukuda, K; Handa, S; Kawamura, Y; Nakamura, Y; Ogawa, S, 1990) |
| "With adrenaline-induced arrhythmias, the three drugs aggravated ventricular tachycardia to produce ventricular fibrillation." | 1.27 | Effects of OPC-8212, a new positive inotropic agent, on canine ventricular arrhythmias. ( Hashimoto, K; Mitsuhashi, H, 1986) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (25.00) | 18.7374 |
| 1990's | 4 (50.00) | 18.2507 |
| 2000's | 1 (12.50) | 29.6817 |
| 2010's | 1 (12.50) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Jia, L | 1 |
| Sun, H | 1 |
| Kayık, G | 1 |
| Tüzün, NŞ | 1 |
| Durdagi, S | 1 |
| Cohn, JN | 1 |
| Goldstein, SO | 1 |
| Greenberg, BH | 1 |
| Lorell, BH | 1 |
| Bourge, RC | 1 |
| Jaski, BE | 1 |
| Gottlieb, SO | 1 |
| McGrew, F | 1 |
| DeMets, DL | 1 |
| White, BG | 1 |
| Yoshimura, A | 1 |
| Yoshioka, K | 1 |
| Hino, M | 1 |
| Sugawara, H | 1 |
| Sakato, M | 1 |
| Endoh, M | 1 |
| Feldman, AM | 1 |
| Baughman, KL | 1 |
| Lee, WK | 1 |
| Gottlieb, SH | 1 |
| Weiss, JL | 1 |
| Becker, LC | 1 |
| Strobeck, JE | 1 |
| Fukuda, K | 2 |
| Handa, S | 2 |
| Ogawa, S | 2 |
| Nakamura, Y | 2 |
| Kawamura, Y | 2 |
| Hashimoto, K | 1 |
| Mitsuhashi, H | 1 |
2 trials available for vesnarinone and Arrhythmia
| Article | Year |
|---|---|
A dose-dependent increase in mortality with vesnarinone among patients with severe heart failure. Vesnarinone Trial Investigators.
Topics: Aged; Agranulocytosis; Angiotensin-Converting Enzyme Inhibitors; Arrhythmias, Cardiac; Cardiotonic A | 1998 |
Usefulness of OPC-8212, a quinolinone derivative, for chronic congestive heart failure in patients with ischemic heart disease or idiopathic dilated cardiomyopathy.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Arrhythmias, Cardiac; Cardiomyopathy, Dilated; Cardioton | 1991 |
6 other studies available for vesnarinone and Arrhythmia
| Article | Year |
|---|---|
Support vector machines classification of hERG liabilities based on atom types.
Topics: Animals; Arrhythmias, Cardiac; CHO Cells; Computer Simulation; Cricetinae; Cricetulus; Discriminant | 2008 |
Structural investigation of vesnarinone at the pore domains of open and open-inactivated states of hERG1 K
Topics: Arrhythmias, Cardiac; ERG1 Potassium Channel; Humans; Molecular Docking Simulation; Molecular Dynami | 2017 |
Investigation on SCH00013, a novel cardiotonic agent with Ca++ sensitizing action. 4th communication: influence on experimentally induced ventricular arrhythmia in dogs.
Topics: Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Calcium Channel Agonists; Cardiotonic Agents; | 1999 |
[How to select newly-developed oral inotropic agents: an evaluation based on their effects on heart rate and arrhythmias].
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Arrhythmias, Cardiac; Atrial Fibrillation; Car | 1990 |
[Usefulness of OPC-8212, an inotropic agent, in patients with chronic congestive heart failure--a multiple dose evaluation on its effect and arrhythmogenesis].
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Arrhythmias, Cardiac; Cardiotonic Agents; Drug | 1988 |
Effects of OPC-8212, a new positive inotropic agent, on canine ventricular arrhythmias.
Topics: Animals; Arrhythmias, Cardiac; Digitalis Glycosides; Dogs; Epinephrine; Female; Heart Ventricles; Ma | 1986 |